# US 2015/0148423 A1 · Use of n-acetylcysteine amide in the treatment of disease and injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148423 A1
- Document ID: US20150148423A1
- Status: Published application
- Kind: A1
- Application number: 14/397,341
- Filed: 2013-04-26
- Published: 2015-05-28
- Earliest claimed: 2012-04-26
- Assignees: Sentient Lifesciences, Inc.
- Applicants: Sentient Lifesciences, Inc.
- Inventors: Glenn A. Goldstein
- Web page: https://patentgrep.com/patent/US20150148423A1

## CPC

- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61P 27/12: for cataracts
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure describes methods of use for N-acetylcysteine amide for the treatment of various disorders

## Claims

### Claim 1

A method of treating contrast induced nephropathy in a subject in need thereof comprising administering to the subject a composition comprising a therapeutically effective amount of N-acetylcysteine amide (NACA).

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable salt or excipient.

### Claim at position 3

3-6. (canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the NACA is administered systemically.

### Claim 8 (depends on 7)

The method of claim 7, wherein the NACA is administered intraperitoneally or intravenously.

### Claim at position 6

9-10. (canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 12 (depends on 11)

The method of claim 11, wherein the mammal is a human.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the NACA is administered at between 5 and 10,000 mg/kg.

### Claim at position 11

15-90. (canceled)
